Institut für Pharmazeutische und Medizinische Chemie, Münster, Germany.
Arch Pharm (Weinheim). 2011 Jul;344(7):415-21. doi: 10.1002/ardp.201000365. Epub 2011 May 20.
Based on the pharmacophore model of Glennon the conformationally restricted σ(1) receptor ligand 2 with a 1,3-dioxane moiety has been designed and synthesized. The three step synthesis (transacetalization with pentane-1,3,5-triol, tosylation, and nucleophilic substitution with benzylamine) provided diastereoselectively the cis-configured 1,3-dioxane 2 in good yields. The 1,3-dioxane 2 represents a potent σ(1) receptor ligand (K(i) = 19 nM) with moderate selectivity over the σ(2) subtype (K(i) = 92 nM) and excellent selectivity against more than 60 other targets. Additionally the hERG K(+) channel is not affected by 2. In the capsaicin assay 2 showed extraordinarily high analgesic activity with more than 70% analgesia at the very low dose of 0.25 mg/kg body weight, which indicates σ(1) antagonistic activity. Since 2 does only interact with σ(1) receptors, the in-vivo antiallodynic activity of 2 must be attributed to the σ(1) antagonistic activity.
基于 Glonn 的药效团模型,设计并合成了具有 1,3-二氧戊环部分的受限构象σ(1)受体配体 2。三步合成(戊烷-1,3,5-三醇的缩醛化、甲苯磺酰化和苄胺的亲核取代)以良好的收率选择性地提供了顺式构型的 1,3-二氧戊环 2。1,3-二氧戊环 2 是一种有效的 σ(1)受体配体(K(i) = 19 nM),对 σ(2)亚型具有中等选择性(K(i) = 92 nM),对 60 多种其他靶点具有优异的选择性。此外,2 对 hERG K(+)通道没有影响。在辣椒素测定中,2 表现出异常高的镇痛活性,在非常低的剂量 0.25 mg/kg 体重下,镇痛活性超过 70%,表明具有 σ(1)拮抗活性。由于 2 仅与 σ(1)受体相互作用,因此 2 的体内抗痛觉过敏活性必须归因于 σ(1)拮抗活性。